X4 Pharmaceuticals’ (XFOR) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR) in a research report sent to investors on Thursday,Benzinga reports. HC Wainwright currently has a $1.50 target price on the stock. HC Wainwright also issued estimates for X4 Pharmaceuticals’ FY2028 earnings at $0.00 EPS and FY2029 earnings at $0.15 EPS.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $3.00 price objective on shares of X4 Pharmaceuticals in a research note on Wednesday.

X4 Pharmaceuticals Price Performance

Shares of X4 Pharmaceuticals stock opened at $0.25 on Thursday. The firm has a market cap of $43.42 million, a P/E ratio of -2.78 and a beta of 0.39. The firm’s 50-day simple moving average is $0.43 and its 200-day simple moving average is $0.52. X4 Pharmaceuticals has a twelve month low of $0.24 and a twelve month high of $1.60. The company has a debt-to-equity ratio of 1.26, a quick ratio of 4.80 and a current ratio of 4.89.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its quarterly earnings data on Tuesday, March 25th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The business had revenue of $1.43 million during the quarter, compared to the consensus estimate of $1.07 million. As a group, research analysts expect that X4 Pharmaceuticals will post -0.68 EPS for the current fiscal year.

Insider Transactions at X4 Pharmaceuticals

In related news, CFO Adam S. Mostafa sold 74,773 shares of the company’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $33,647.85. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Paula Ragan sold 76,473 shares of the stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $34,412.85. Following the sale, the chief executive officer now directly owns 1,087,386 shares in the company, valued at approximately $489,323.70. This represents a 6.57 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 202,663 shares of company stock valued at $91,198. Corporate insiders own 1.62% of the company’s stock.

Hedge Funds Weigh In On X4 Pharmaceuticals

Large investors have recently modified their holdings of the stock. Cantor Fitzgerald L. P. acquired a new stake in shares of X4 Pharmaceuticals in the fourth quarter valued at approximately $30,000. Verition Fund Management LLC bought a new stake in shares of X4 Pharmaceuticals during the third quarter worth $30,000. Atria Wealth Solutions Inc. acquired a new position in shares of X4 Pharmaceuticals during the fourth quarter valued at $44,000. Wells Fargo & Company MN boosted its holdings in X4 Pharmaceuticals by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 78,518 shares of the company’s stock valued at $58,000 after acquiring an additional 26,763 shares during the last quarter. Finally, Bank of America Corp DE increased its position in X4 Pharmaceuticals by 20.3% in the fourth quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock worth $98,000 after purchasing an additional 22,485 shares during the period. 72.03% of the stock is currently owned by institutional investors and hedge funds.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.